At first, it was tentative. But now almost all parts of the U.S. healthcare system are racing to adopt some form of artificial intelligence. Some leaders caution about using it too widely, too fast.

The exact cause of amyotrophic lateral sclerosis (ALS) has long remained a mystery, but new research demonstrates that there is an autoimmune component to the disease.

Novo Nordisk has a factor VIII mimetic in a phase 3 trial, and a Chinese company is forging ahead with its gene therapy product.

Patients with vitiligo face important treatment decisions when choosing between topical and systemic therapies, each offering distinct advantages and challenges. Chesahna Kindred, MD, MBA, FAAD, ...

State healthcare plans struggling to pay for multimillion-dollar gene therapies got a lifeline this summer when the federal government launched a novel plan to negotiate fees and rebates to cover the ...

Aetna has released the details of its Medicare Advantage plans for 2026, which focus on preventative care and drug cost savings.

The FDA approved the system in September 2025. A novel drug-delivery system has demonstrated effectiveness in treating specific bladder cancer patients whose tumors previously did not respond to ...

Promoting interdisciplinary collaboration via molecular tumor boards and shared decision-making frameworks might improve the precision and applicability of testing in clinical settings, according to a ...

Humana announces its 2026 Medicare Advantage and prescription drug plans, focusing on stable benefits, preventive care and enhanced member support.

Expedited regulatory paths transform colorectal cancer treatment, enhancing access but creating challenges in clinical evidence and payer decisions.

Many potential colorectal biomarkers are only studied once. A remarkably low translation rate of 0.14% of colorectal cancer (CRC) biomarkers have been approved for patient care. The lack of approval ...

The Chinorec trial reveals that combining Yervoy and Opdivo with chemoradiotherapy is safe for rectal cancer, though response rates remain unchanged.